-
1
-
-
70949107842
-
Inflammatory bowel disease
-
Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
-
(2009)
N Engl J Med
, vol.361
, pp. 2066-2078
-
-
Abraham, C.1
Cho, J.H.2
-
3
-
-
34547176642
-
Unravelling the pathogenesis of inflammatory bowel disease
-
Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
-
(2007)
Nature
, vol.448
, pp. 427-434
-
-
Xavier, R.J.1
Podolsky, D.K.2
-
4
-
-
33847381116
-
The fundamental basis of inflammatory bowel disease
-
Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
-
(2007)
J Clin Invest
, vol.117
, pp. 514-521
-
-
Strober, W.1
Fuss, I.2
Mannon, P.3
-
5
-
-
79955551587
-
Regulation of homeostasis and inflammation in the intestine
-
MacDonald T.T., Monteleone I., Fantini M.C., Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011, 140:1768-1775.
-
(2011)
Gastroenterology
, vol.140
, pp. 1768-1775
-
-
MacDonald, T.T.1
Monteleone, I.2
Fantini, M.C.3
Monteleone, G.4
-
6
-
-
0030209985
-
Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
-
Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996, 157:1261-1270.
-
(1996)
J Immunol
, vol.157
, pp. 1261-1270
-
-
Fuss, I.J.1
Neurath, M.2
Boirivant, M.3
Klein, J.S.4
de la Motte, C.5
Strong, S.A.6
-
7
-
-
0034677646
-
A novel transcription factor, T-bet, directs Th1 lineage commitment
-
Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
-
(2000)
Cell
, vol.100
, pp. 655-669
-
-
Szabo, S.J.1
Kim, S.T.2
Costa, G.L.3
Zhang, X.4
Fathman, C.G.5
Glimcher, L.H.6
-
8
-
-
0035314015
-
Stability and commitment in T helper cell development
-
Asnagli H., Murphy K.M. Stability and commitment in T helper cell development. Curr Opin Immunol 2001, 13:242-247.
-
(2001)
Curr Opin Immunol
, vol.13
, pp. 242-247
-
-
Asnagli, H.1
Murphy, K.M.2
-
9
-
-
0030995575
-
Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
-
Monteleone G., Biancone L., Marasco R., Morrone G., Marasco O., Luzza F., et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997, 112:1169-1178.
-
(1997)
Gastroenterology
, vol.112
, pp. 1169-1178
-
-
Monteleone, G.1
Biancone, L.2
Marasco, R.3
Morrone, G.4
Marasco, O.5
Luzza, F.6
-
10
-
-
23944521291
-
Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease
-
Gordon J.N., MacDonald T.T. Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease. Gut 2005, 54:1213-1215.
-
(2005)
Gut
, vol.54
, pp. 1213-1215
-
-
Gordon, J.N.1
MacDonald, T.T.2
-
11
-
-
0033168120
-
Bioactive IL-18 expression is up-regulated in Crohn's disease
-
Monteleone G., Trapasso F., Parrello T., Biancone L., Stella A., Iuliano R., et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999, 163:143-147.
-
(1999)
J Immunol
, vol.163
, pp. 143-147
-
-
Monteleone, G.1
Trapasso, F.2
Parrello, T.3
Biancone, L.4
Stella, A.5
Iuliano, R.6
-
12
-
-
0034176003
-
IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production
-
Liu Z., Geboes K., Colpaert S., D'Haens G.R., Rutgeerts P., Ceuppens J.L. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 2000, 164:3608-3615.
-
(2000)
J Immunol
, vol.164
, pp. 3608-3615
-
-
Liu, Z.1
Geboes, K.2
Colpaert, S.3
D'Haens, G.R.4
Rutgeerts, P.5
Ceuppens, J.L.6
-
13
-
-
0028861975
-
Antibodies to interleukin 12 abrogate established experimental colitis in mice
-
Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281-1290.
-
(1995)
J Exp Med
, vol.182
, pp. 1281-1290
-
-
Neurath, M.F.1
Fuss, I.2
Kelsall, B.L.3
Stuber, E.4
Strober, W.5
-
14
-
-
0033558364
-
Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens
-
Wirtz S., Finotto S., Kanzler S., Lohse A.W., Blessing M., Lehr H.A., et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. J Immunol 1999, 162:1884-1888.
-
(1999)
J Immunol
, vol.162
, pp. 1884-1888
-
-
Wirtz, S.1
Finotto, S.2
Kanzler, S.3
Lohse, A.W.4
Blessing, M.5
Lehr, H.A.6
-
15
-
-
0032530697
-
IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice
-
Davidson N.J., Hudak S.A., Lesley R.E., Menon S., Leach M.W., Rennick D.M. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998, 161:3143-3149.
-
(1998)
J Immunol
, vol.161
, pp. 3143-3149
-
-
Davidson, N.J.1
Hudak, S.A.2
Lesley, R.E.3
Menon, S.4
Leach, M.W.5
Rennick, D.M.6
-
16
-
-
33746176176
-
Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
-
Hommes D.W., Mikhajlova T.L., Stoinov S., Stimac D., Vucelic B., Lonovics J., et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006, 55:1131-1137.
-
(2006)
Gut
, vol.55
, pp. 1131-1137
-
-
Hommes, D.W.1
Mikhajlova, T.L.2
Stoinov, S.3
Stimac, D.4
Vucelic, B.5
Lonovics, J.6
-
17
-
-
73949092345
-
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
-
Reinisch W., de Villiers W., Bene L., Simon L., Racz I., Katz S., et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010, 16:233-242.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 233-242
-
-
Reinisch, W.1
de Villiers, W.2
Bene, L.3
Simon, L.4
Racz, I.5
Katz, S.6
-
18
-
-
33746132472
-
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease
-
Reinisch W., Hommes D.W., Van Assche G., Colombel J.F., Gendre J.P., Oldenburg B., et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006, 55:1138-1144.
-
(2006)
Gut
, vol.55
, pp. 1138-1144
-
-
Reinisch, W.1
Hommes, D.W.2
Van Assche, G.3
Colombel, J.F.4
Gendre, J.P.5
Oldenburg, B.6
-
19
-
-
8344284998
-
Anti-interleukin-12 antibody for active Crohn's disease
-
Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004, 351:2069-2079.
-
(2004)
N Engl J Med
, vol.351
, pp. 2069-2079
-
-
Mannon, P.J.1
Fuss, I.J.2
Mayer, L.3
Elson, C.O.4
Sandborn, W.J.5
Present, D.6
-
20
-
-
53049091561
-
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
-
Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
-
(2008)
Gastroenterology
, vol.135
, pp. 1130-1141
-
-
Sandborn, W.J.1
Feagan, B.G.2
Fedorak, R.N.3
Scherl, E.4
Fleisher, M.R.5
Katz, S.6
-
21
-
-
84871701834
-
Ustekinumab induction and maintenance therapy in refractory Crohn's disease
-
Sandborn W.J., Gasink C., Gao L.L., Blank M.A., Johanns J., Guzzo C., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012, 367:1519-1528.
-
(2012)
N Engl J Med
, vol.367
, pp. 1519-1528
-
-
Sandborn, W.J.1
Gasink, C.2
Gao, L.L.3
Blank, M.A.4
Johanns, J.5
Guzzo, C.6
-
22
-
-
67650224449
-
Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease
-
Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009, 58:1152-1167.
-
(2009)
Gut
, vol.58
, pp. 1152-1167
-
-
Brand, S.1
-
23
-
-
84860996207
-
Th17-related cytokines in inflammatory bowel diseases: friends or foes?
-
Monteleone I., Sarra M., Pallone F., Monteleone G. Th17-related cytokines in inflammatory bowel diseases: friends or foes?. Curr Mol Med 2012, 12:592-597.
-
(2012)
Curr Mol Med
, vol.12
, pp. 592-597
-
-
Monteleone, I.1
Sarra, M.2
Pallone, F.3
Monteleone, G.4
-
24
-
-
77954395263
-
IL-23/IL-17 axis in IBD
-
Sarra M., Pallone F., Macdonald T.T., Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 2010, 16:1808-1813.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 1808-1813
-
-
Sarra, M.1
Pallone, F.2
Macdonald, T.T.3
Monteleone, G.4
-
25
-
-
84868680312
-
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
-
Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
-
(2012)
Gut
, vol.61
, pp. 1693-1700
-
-
Hueber, W.1
Sands, B.E.2
Lewitzky, S.3
Vandemeulebroecke, M.4
Reinisch, W.5
Higgins, P.D.6
-
26
-
-
0036142235
-
Distinct inflammatory mechanisms mediate early versus late colitis in mice
-
Spencer D.M., Veldman G.M., Banerjee S., Willis J., Levine A.D. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002, 122:94-105.
-
(2002)
Gastroenterology
, vol.122
, pp. 94-105
-
-
Spencer, D.M.1
Veldman, G.M.2
Banerjee, S.3
Willis, J.4
Levine, A.D.5
-
27
-
-
36749038197
-
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease
-
Kugathasan S., Saubermann L.J., Smith L., Kou D., Itoh J., Binion D.G., et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007, 56:1696-1705.
-
(2007)
Gut
, vol.56
, pp. 1696-1705
-
-
Kugathasan, S.1
Saubermann, L.J.2
Smith, L.3
Kou, D.4
Itoh, J.5
Binion, D.G.6
-
28
-
-
34247586091
-
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis
-
Fichtner-Feigl S., Fuss I.J., Young C.A., Watanabe T., Geissler E.K., Schlitt H.J., et al. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007, 178:5859-5870.
-
(2007)
J Immunol
, vol.178
, pp. 5859-5870
-
-
Fichtner-Feigl, S.1
Fuss, I.J.2
Young, C.A.3
Watanabe, T.4
Geissler, E.K.5
Schlitt, H.J.6
-
29
-
-
44949221585
-
An insight into molecular mechanisms of human T helper cell differentiation
-
Rautajoki K.J., Kylaniemi M.K., Raghav S.K., Rao K., Lahesmaa R. An insight into molecular mechanisms of human T helper cell differentiation. Ann Med 2008, 40:322-335.
-
(2008)
Ann Med
, vol.40
, pp. 322-335
-
-
Rautajoki, K.J.1
Kylaniemi, M.K.2
Raghav, S.K.3
Rao, K.4
Lahesmaa, R.5
-
30
-
-
15744390341
-
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease
-
Monteleone G., Monteleone I., Fina D., Vavassori P., Del Vecchio Blanco G., Caruso R., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005, 128:687-694.
-
(2005)
Gastroenterology
, vol.128
, pp. 687-694
-
-
Monteleone, G.1
Monteleone, I.2
Fina, D.3
Vavassori, P.4
Del Vecchio Blanco, G.5
Caruso, R.6
-
31
-
-
41349121555
-
Regulation of gut inflammation and th17 cell response by interleukin-21
-
Fina D., Sarra M., Fantini M.C., Rizzo A., Caruso R., Caprioli F., et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008, 134:1038-1048.
-
(2008)
Gastroenterology
, vol.134
, pp. 1038-1048
-
-
Fina, D.1
Sarra, M.2
Fantini, M.C.3
Rizzo, A.4
Caruso, R.5
Caprioli, F.6
-
32
-
-
23244455992
-
Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution
-
Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
-
(2005)
Gastroenterology
, vol.129
, pp. 550-564
-
-
Heller, F.1
Florian, P.2
Bojarski, C.3
Richter, J.4
Christ, M.5
Hillenbrand, B.6
-
33
-
-
54349118972
-
The role of IL-13 and NK T cells in experimental and human ulcerative colitis
-
Fuss I.J., Strober W. The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol 2008, 1(1 Suppl.):S31-S33.
-
(2008)
Mucosal Immunol
, vol.1
, Issue.1 SUPPL.
-
-
Fuss, I.J.1
Strober, W.2
-
34
-
-
0036850908
-
Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells
-
Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002, 17:629-638.
-
(2002)
Immunity
, vol.17
, pp. 629-638
-
-
Heller, F.1
Fuss, I.J.2
Nieuwenhuis, E.E.3
Blumberg, R.S.4
Strober, W.5
-
35
-
-
79952532799
-
Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production
-
Mannon P.J., Hornung R.L., Yang Z., Yi C., Groden C., Friend J., et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 2011, 60:449-455.
-
(2011)
Gut
, vol.60
, pp. 449-455
-
-
Mannon, P.J.1
Hornung, R.L.2
Yang, Z.3
Yi, C.4
Groden, C.5
Friend, J.6
-
36
-
-
84865013186
-
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
-
Sandborn W.J., Ghosh S., Panes J., Vranic I., Su C., Rousell S., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012, 367:616-624.
-
(2012)
N Engl J Med
, vol.367
, pp. 616-624
-
-
Sandborn, W.J.1
Ghosh, S.2
Panes, J.3
Vranic, I.4
Su, C.5
Rousell, S.6
-
38
-
-
69949133374
-
Chemokines as novel therapeutic targets for inflammatory bowel disease
-
Nishimura M., Kuboi Y., Muramoto K., Kawano T., Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci 2009, 1173:350-356.
-
(2009)
Ann N Y Acad Sci
, vol.1173
, pp. 350-356
-
-
Nishimura, M.1
Kuboi, Y.2
Muramoto, K.3
Kawano, T.4
Imai, T.5
-
39
-
-
33750716541
-
Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis
-
Rivera-Nieves J., Ho J., Bamias G., Ivashkina N., Ley K., Oppermann M., et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006, 131:1518-1529.
-
(2006)
Gastroenterology
, vol.131
, pp. 1518-1529
-
-
Rivera-Nieves, J.1
Ho, J.2
Bamias, G.3
Ivashkina, N.4
Ley, K.5
Oppermann, M.6
-
40
-
-
77954126169
-
GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease
-
Eksteen B., Adams D.H. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. Drugs 2010, 13:472-781.
-
(2010)
Drugs
, vol.13
, pp. 472-781
-
-
Eksteen, B.1
Adams, D.H.2
-
41
-
-
79955396012
-
The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice
-
Wermers J.D., McNamee E.N., Wurbel M.A., Jedlicka P., Rivera-Nieves J. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology 2011, 140:1526-1535.
-
(2011)
Gastroenterology
, vol.140
, pp. 1526-1535
-
-
Wermers, J.D.1
McNamee, E.N.2
Wurbel, M.A.3
Jedlicka, P.4
Rivera-Nieves, J.5
-
42
-
-
0034903450
-
A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease
-
Gordon F.H., Lai C.W., Hamilton M.I., Allison M.C., Srivastava E.D., Fouweather M.G., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001, 121:268-274.
-
(2001)
Gastroenterology
, vol.121
, pp. 268-274
-
-
Gordon, F.H.1
Lai, C.W.2
Hamilton, M.I.3
Allison, M.C.4
Srivastava, E.D.5
Fouweather, M.G.6
-
43
-
-
27644441529
-
Natalizumab induction and maintenance therapy for Crohn's disease
-
Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
-
(2005)
N Engl J Med
, vol.353
, pp. 1912-1925
-
-
Sandborn, W.J.1
Colombel, J.F.2
Enns, R.3
Feagan, B.G.4
Hanauer, S.B.5
Lawrance, I.C.6
-
44
-
-
20444469332
-
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin
-
Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Pare P., McDonald J.W., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
-
(2005)
N Engl J Med
, vol.352
, pp. 2499-2507
-
-
Feagan, B.G.1
Greenberg, G.R.2
Wild, G.3
Fedorak, R.N.4
Pare, P.5
McDonald, J.W.6
-
45
-
-
79953801792
-
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis
-
Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 644-659
-
-
Ford, A.C.1
Sandborn, W.J.2
Khan, K.J.3
Hanauer, S.B.4
Talley, N.J.5
Moayyedi, P.6
-
46
-
-
0036263171
-
P53 negatively regulates intestinal immunity by delaying mucosal T cell cycling
-
Sturm A., Itoh J., Jacobberger J.W., Fiocchi C. p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest 2002, 109:1481-1492.
-
(2002)
J Clin Invest
, vol.109
, pp. 1481-1492
-
-
Sturm, A.1
Itoh, J.2
Jacobberger, J.W.3
Fiocchi, C.4
-
47
-
-
33847000579
-
Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications
-
Mudter J., Neurath M.F. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007, 56:293-303.
-
(2007)
Gut
, vol.56
, pp. 293-303
-
-
Mudter, J.1
Neurath, M.F.2
-
48
-
-
79957673711
-
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
-
Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011, 22:83-89.
-
(2011)
Cytokine Growth Factor Rev
, vol.22
, pp. 83-89
-
-
Neurath, M.F.1
Finotto, S.2
-
49
-
-
0036151047
-
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
-
ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
-
(2002)
Gut
, vol.50
, pp. 206-211
-
-
ten Hove, T.1
van Montfrans, C.2
Peppelenbosch, M.P.3
van Deventer, S.J.4
-
50
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
-
Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
van Deventer, S.J.3
Mayer, L.4
Present, D.H.5
Braakman, T.6
-
51
-
-
32044451548
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
-
Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeerts, P.3
Fedorak, R.N.4
Lukas, M.5
MacIntosh, D.6
-
52
-
-
0034754477
-
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial
-
Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
-
(2001)
Gastroenterology
, vol.121
, pp. 1088-1094
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Katz, S.3
Safdi, M.4
Wolf, D.G.5
Baerg, R.D.6
-
53
-
-
33646164362
-
Transforming growth factor-beta regulation of immune responses
-
Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99-146.
-
(2006)
Annu Rev Immunol
, vol.24
, pp. 99-146
-
-
Li, M.O.1
Wan, Y.Y.2
Sanjabi, S.3
Robertson, A.K.4
Flavell, R.A.5
-
54
-
-
0034894059
-
Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease
-
Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., MacDonald T.T. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001, 108:601-609.
-
(2001)
J Clin Invest
, vol.108
, pp. 601-609
-
-
Monteleone, G.1
Kumberova, A.2
Croft, N.M.3
McKenzie, C.4
Steer, H.W.5
MacDonald, T.T.6
-
55
-
-
19344374130
-
Smad7 in TGF-beta-mediated negative regulation of gut inflammation
-
Monteleone G., Pallone F., MacDonald T.T. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol 2004, 25:513-517.
-
(2004)
Trends Immunol
, vol.25
, pp. 513-517
-
-
Monteleone, G.1
Pallone, F.2
MacDonald, T.T.3
-
56
-
-
54349127897
-
TGF-beta1 and Smad7 in the regulation of IBD
-
Monteleone G., Boirivant M., Pallone F., MacDonald T.T. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 2008, 1(1 Suppl.):S50-S53.
-
(2008)
Mucosal Immunol
, vol.1
, Issue.1 SUPPL.
-
-
Monteleone, G.1
Boirivant, M.2
Pallone, F.3
MacDonald, T.T.4
-
57
-
-
33845647693
-
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis
-
Boirivant M., Pallone F., Di Giacinto C., Fina D., Monteleone I., Marinaro M., et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 2006, 131:1786-1798.
-
(2006)
Gastroenterology
, vol.131
, pp. 1786-1798
-
-
Boirivant, M.1
Pallone, F.2
Di Giacinto, C.3
Fina, D.4
Monteleone, I.5
Marinaro, M.6
-
58
-
-
84859439270
-
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease
-
Monteleone G., Fantini M.C., Onali S., Zorzi F., Sancesario G., Bernardini S., et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012, 20:870-876.
-
(2012)
Mol Ther
, vol.20
, pp. 870-876
-
-
Monteleone, G.1
Fantini, M.C.2
Onali, S.3
Zorzi, F.4
Sancesario, G.5
Bernardini, S.6
-
59
-
-
84878568056
-
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease
-
Zorzi F., Calabrese E., Monteleone I., Fantini M., Onali S., Biancone L., et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther 2012, 36:850-857.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 850-857
-
-
Zorzi, F.1
Calabrese, E.2
Monteleone, I.3
Fantini, M.4
Onali, S.5
Biancone, L.6
-
60
-
-
0027521572
-
Interleukin-10-deficient mice develop chronic enterocolitis
-
Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
-
(1993)
Cell
, vol.75
, pp. 263-274
-
-
Kuhn, R.1
Lohler, J.2
Rennick, D.3
Rajewsky, K.4
Muller, W.5
-
61
-
-
70949087383
-
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor
-
Glocker E.O., Kotlarz D., Boztug K., Gertz E.M., Schaffer A.A., Noyan F., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009, 361:2033-2045.
-
(2009)
N Engl J Med
, vol.361
, pp. 2033-2045
-
-
Glocker, E.O.1
Kotlarz, D.2
Boztug, K.3
Gertz, E.M.4
Schaffer, A.A.5
Noyan, F.6
-
62
-
-
84864206050
-
Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy
-
Kotlarz D., Beier R., Murugan D., Diestelhorst J., Jensen O., Boztug K., et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012, 143:347-355.
-
(2012)
Gastroenterology
, vol.143
, pp. 347-355
-
-
Kotlarz, D.1
Beier, R.2
Murugan, D.3
Diestelhorst, J.4
Jensen, O.5
Boztug, K.6
-
63
-
-
0034463305
-
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group
-
Fedorak R.N., Gangl A., Elson C.O., Rutgeerts P., Schreiber S., Wild G., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119:1473-1482.
-
(2000)
Gastroenterology
, vol.119
, pp. 1473-1482
-
-
Fedorak, R.N.1
Gangl, A.2
Elson, C.O.3
Rutgeerts, P.4
Schreiber, S.5
Wild, G.6
-
64
-
-
66149156478
-
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut
-
Caruso R., Sarra M., Stolfi C., Rizzo A., Fina D., Fantini M.C., et al. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 2009, 136:2270-2279.
-
(2009)
Gastroenterology
, vol.136
, pp. 2270-2279
-
-
Caruso, R.1
Sarra, M.2
Stolfi, C.3
Rizzo, A.4
Fina, D.5
Fantini, M.C.6
-
65
-
-
18244387204
-
Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells
-
Rimoldi M., Chieppa M., Salucci V., Avogadri F., Sonzogni A., Sampietro G.M., et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005, 6:507-514.
-
(2005)
Nat Immunol
, vol.6
, pp. 507-514
-
-
Rimoldi, M.1
Chieppa, M.2
Salucci, V.3
Avogadri, F.4
Sonzogni, A.5
Sampietro, G.M.6
-
66
-
-
38849141814
-
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis
-
Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
-
(2008)
J Clin Invest
, vol.118
, pp. 534-544
-
-
Sugimoto, K.1
Ogawa, A.2
Mizoguchi, E.3
Shimomura, Y.4
Andoh, A.5
Bhan, A.K.6
-
67
-
-
79959918506
-
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract
-
Monteleone I., Rizzo A., Sarra M., Sica G., Sileri P., Biancone L., et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011, 141:237-248.
-
(2011)
Gastroenterology
, vol.141
, pp. 237-248
-
-
Monteleone, I.1
Rizzo, A.2
Sarra, M.3
Sica, G.4
Sileri, P.5
Biancone, L.6
-
68
-
-
84857657607
-
Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies
-
Bogdanos D.P., Rigopoulou E.I., Smyk D.S., Roggenbuck D., Reinhold D., Forbes A., et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev 2011, 11:143-148.
-
(2011)
Autoimmun Rev
, vol.11
, pp. 143-148
-
-
Bogdanos, D.P.1
Rigopoulou, E.I.2
Smyk, D.S.3
Roggenbuck, D.4
Reinhold, D.5
Forbes, A.6
-
69
-
-
3342988481
-
Inflammatory bowel disease: the role of environmental factors
-
Danese S., Sans M., Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004, 3:394-400.
-
(2004)
Autoimmun Rev
, vol.3
, pp. 394-400
-
-
Danese, S.1
Sans, M.2
Fiocchi, C.3
-
70
-
-
77649233106
-
The geoepidemiology of autoimmune intestinal diseases
-
Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9:A372-A378.
-
(2010)
Autoimmun Rev
, vol.9
-
-
Logan, I.1
Bowlus, C.L.2
|